Day: March 12, 2024

Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on March 12, 2024. Posted in Earnings Releases And Operating Results.

Accelerated fourth quarter sales growth to 7.6%, organic growth* of 14.3% Appointed Rob Claypoole as President and Chief Executive Officer, bringing more than 20 years of leadership experience in the global medical device industry Provides full-year 2024 financial guidance reflecting enhanced revenue growth and improved executionDURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2023, and provided its financial guidance for full-year 2024. “We returned to revenue growth, significantly improved adjusted EBITDA, and further enhanced our liquidity position as a result of our team’s strong execution in the fourth quarter of 2023,”...

SIGA Declares Special Cash Dividend of $0.60 Per Share

Written by Customer Service on March 12, 2024. Posted in Dividend Reports And Estimates.

Represents a $0.15 Per Share Increase Over 2023 Special Dividend NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company’s common stock. This represents an increase of $0.15 per share, or 33%, over the cash dividend paid in June 2023. The dividend is payable on April 11, 2024, to shareholders of record at the close of business on March 26, 2024. “Our operating performance, strong cash resources, and continued confidence in SIGA’s business position us to declare a special cash dividend for our shareholders,” said Diem Nguyen, Chief Executive Officer. “The significant increase in the dividend compared with the prior-year dividend reflects our active...

Philips and AWS collaborate to scale digital pathology in the cloud, enhancing diagnostic capabilities and improving productivity

Written by Customer Service on March 12, 2024. Posted in Public Companies.

Integrated DiagnosticsPathology ScannerDigital PathologyMarch 12, 2024Cloud offering will help improve workflow integration, access, and reliability, delivering greater productivity and collaboration Collaboration combines best of clinical workflow leadership with scalable cloud solution to help accelerate decision-making and further transform patient careAmsterdam, the Netherlands and Orlando, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced an expanded collaboration with Amazon Web Services (AWS) to address the growing need for secure, scalable digital pathology solutions in the cloud. The collaboration unites Philips’ leadership and expertise in digitization of pathology to optimize clinical workflows and AWS’ leadership in scalable, secure cloud solutions. Philips...

Inspired Launches Virtual Sports with Rush Street Interactive on BetRivers in NJ

Written by Customer Service on March 12, 2024. Posted in Public Companies.

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) — Inspired Entertainment, Inc. (“Inspired” or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, systems, and solutions, is proud to announce the launch of its best-in-class Virtual Sports content in New Jersey through a partnership with Rush Street Interactive, Inc. (NYSE: RSI) (“RSI”), a leading online sports betting and casino company in the United States. Inspired’s Virtual Sports content is now accessible to BetRivers players through its renowned BetRivers sportsbook and casino, providing players in New Jersey an engaging experience. This launch is the first of many planned across other states with RSI in the coming year. “We are thrilled to partner with RSI to bring Inspired’s premium Virtual Sports to BetRivers players in New Jersey. This collaboration...

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Written by Customer Service on March 12, 2024. Posted in Public Companies.

MIAMI, March 12, 2024 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced the appointment of Louis Aronne, MD, as Chief Medical Advisor and a member of the Scientific Advisory Board to support the advancement of enobosarm, an oral novel selective androgen receptor modulator (SARM), to avoid muscle loss and augment fat loss when combined with a Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drug for potentially higher quality weight loss. Dr. Louis Aronne is a leading authority on obesity and its treatment. He is the Sanford I. Weill Professor of Metabolic Research and the director of the Comprehensive Weight...

Recce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advance

Written by Customer Service on March 12, 2024. Posted in Public Companies.

SYDNEY, Australia, March 12, 2024 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced it received AUD $11,178,965 as a research and development (R&D) advance with Endpoints Capital, capturing Recce’s R&D tax incentive for the 2023/2024 fiscal year (FY23/24) and 2025 fiscal year (FY25). Recce received $11.17 million in non-dilutive cash, reflecting R&D rebate credits for FY23/24, in addition to future anticipated R&D applicable expenditure for FY25. This enables the Company to leverage its R&D expenditure benefits of the past, present, and future R&D applicable expenditure on a here-today basis, as achieved by this agreement. “Securing this advanced funding from Endpoints is a testament to...

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Written by Customer Service on March 12, 2024. Posted in Public Companies.

Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC Clinical data on track for Q3 2024 in Phase 2 trial of BDTX-1535 in 2L/3L patients with acquired resistance or non-classical EGFRm NSCLC Oral presentation at AACR annual meeting in April 2024 describing real world evidence of an evolving EGFR mutation landscape in NSCLC, and the potential of BDTX-1535 to benefit patients across multiple lines of therapy Additional planned data releases for 2024 include GBM results for BDTX-1535 in Q2, and initial results for BDTX-4933 in non-G12C KRASm NSCLC in Q4 Cash, cash equivalents, and investments of $131.4 million as of December 31, 2023, expected to be sufficient to fund operations into the second quarter of 2025CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) — Black Diamond Therapeutics,...

Auddia Announces Partnership with Podcast Industry Leader, Sounds Profitable; Provides Update on Enhanced Podcasts

Written by Customer Service on March 12, 2024. Posted in Public Companies.

Partnership with Sounds Profitable will support a renewed focus on SaaS and integration partnerships for Auddia’s podcast technology Auddia continues discussions with podcast publishers, offering improved economics through subscription BOULDER, CO, March 12, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) (“Auddia” or the “Company”), a proprietary AI platform for audio identification and classification and related technologies, reinventing how consumers engage with AM/FM radio, podcasts, and other audio content, today announced a partnership with Sounds Profitable, a leading research and advocacy firm in podcasting. “We’re delighted to kick off this partnership,” said Michael Lawless, CEO of Auddia. “While we were developing our latest AI and Natural Language Processing (NLP) technologies...

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on March 12, 2024. Posted in Public Companies.

IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient data IK-595 Phase I dose escalation study currently recruiting targeted patients Closed 2023 in a strong financial position with $175M; runway into 2H 2026 BOSTON, March 12, 2024 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full year ending December 31, 2023. The Company also provided an update across the organization and pipeline. “We are diligently executing on our clinical programs while we strive to broaden...

Core Molding Technologies Reports Full Year and Fourth Quarter 2023 Results

Written by Customer Service on March 12, 2024. Posted in Public Companies.

Significant Cash Flow and Improved Returns from Fiscal 2023 Strategic Initiatives COLUMBUS, Ohio, March 12, 2024 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico, today reported financial and operating results for the fiscal periods ended December 31, 2023. Fiscal Year 2023 HighlightsNet sales of $357.7 million, down 5.2% from $377.4 million in the prior year; and product sales of $347.4 million, down 3.2% from the prior year. Sales declined primarily due to lower end-market demand in building products and industrial and utility...

Day: March 12, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice